2 Stocks Down 28% and 34% to Buy and Hold

TransMedics and SoFi shares have fallen 28% and 34%, respectively, over the past year, creating a potential long-term buying opportunity despite near-term pressures. TransMedics' Q2 revenue rose 21% year over year to $189.9 million, but adjusted EPS fell 52% to $0.44 as it invests in kidney-transplant approvals and logistics capabilities. SoFi delivered Q2 revenue growth of 43% to $1.2 billion and net-income growth of 61% to $156.6 million, but weaker-than-expected guidance and interest-rate uncertainty weigh on its lending outlook; membership rose 35% to 15.8 million.

Analysis

TMDX is best viewed as an execution-duration story rather than a simple medtech multiple reset. The logistics build can create a moat because transplant centers value reliability and scheduling control, but it also converts the model toward a capital- and labor-intensive service network; utilization per aircraft/team and contribution margin, not kidney approval alone, will determine whether investment becomes operating leverage. A kidney indication expands the addressable market, yet it could initially worsen margins if capacity is added ahead of case volume; reimbursement coverage and center adoption are the gating variables over the next 6-18 months.

SOFI's key debate is not member growth but whether cross-sell lowers acquisition cost quickly enough to offset a potentially less favorable net-interest-income backdrop and normalize consumer-credit losses. Its deposit-funded model should be structurally advantaged versus non-bank consumer lenders in a rate-cutting cycle, but lower rates can also compress asset yields faster than funding costs once deposit repricing bottoms. The more consequential upside catalyst over 1-3 quarters is sustained fee-based revenue and tangible product-per-member expansion, which would justify valuation separation from lending-heavy fintech peers such as UPST and LC.

Consensus may be too willing to treat both drawdowns as equivalent "buy-the-dip" opportunities. TMDX has idiosyncratic operational risk and a binary margin inflection, while SOFI has more transparent quarterly evidence points but remains exposed to macro credit and rate expectations. Neither warrants chasing on a broad risk-on move; the superior entry is after verification that the respective incremental investments are producing unit-economics improvement.

Key Decisions for Investors

• TMDX: maintain a watch-list long rather than initiate a full position before the next earnings release. Enter only if management shows improving logistics utilization/contribution margin while maintaining growth; target a 6-18 month rerating from demonstrated operating leverage. Falsify on another material margin-guide reduction, weak utilization disclosure, or evidence kidney commercialization requires materially higher fixed-cost investment.
• SOFI: accumulate a 3-6 month long on post-earnings weakness if credit-quality metrics and deposit growth remain stable; use a 5-7% portfolio stop tied to a deterioration in charge-offs or a reduction in full-year EBITDA/earnings guidance. The upside is multiple expansion if fee revenue and cross-sell reduce dependence on lending spreads; the downside is a rate-driven NII reset plus consumer-credit normalization.
• Pair expression: long SOFI / short UPST over the next 6-12 months. SOFI's bank funding and diversified product set should outperform if rates decline gradually and credit remains benign, while UPST retains greater funding-market and underwriting-model sensitivity. Exit if SOFI's charge-offs accelerate faster than UPST's or if policy rates remain restrictive enough to preserve high-spread lending economics.
• For TMDX, set an alert around reimbursement and transplant-center adoption data rather than FDA headlines alone. A favorable approval without evidence of payer coverage, organ-volume growth, and logistics throughput is not a sufficient catalyst for a durable long.